Ligand Pharmaceuticals (FRA:LGDN) LT-Debt-to-Total-Asset: 0.29 (As of Mar. 2026)

What is Ligand Pharmaceuticals LT-Debt-to-Total-Asset?

Ligand Pharmaceuticals FRA:LGDN +5.26% 73 LT-Debt-to-Total-Asset is 0.29 as of Mar. 2026. GuruFocus rates FRA:LGDN with a GF Score™ of 73/100 and a GF Value™ of €150.43 (Significantly Overvalued). The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Ligand Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.29.

Ligand Pharmaceuticals's long-term debt to total assets ratio increased from Mar. 2025 (0.00) to Mar. 2026 (0.29). It may suggest that Ligand Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Ligand Pharmaceuticals (FRA:LGDN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Ligand Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Ligand Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Ligand Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ligand Pharmaceuticals LT-Debt-to-Total-Asset Chart

Ligand Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.25

0.01

0.29

Ligand Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.00	0.01	0.31	0.29	0.29

73GF Score

Ligand Pharmaceuticals Inc FRA:LGDN

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Ligand Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Ligand Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	384.638	/	1332.784
	=	0.29

Ligand Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	390.019	/	1325.271
	=	0.29

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.29 mean?

Ligand Pharmaceuticals (FRA:LGDN) has a LT-Debt-to-Total-Asset of 0.29 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Ligand Pharmaceuticals and its competitors.

Is Ligand Pharmaceuticals' LT-Debt-to-Total-Asset too high?

Ligand Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.29. Overall, Ligand Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Ligand Pharmaceuticals' LT-Debt-to-Total-Asset compare to DFTX and CGON?

Ligand Pharmaceuticals' LT-Debt-to-Total-Asset of 0.29 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Ligand Pharmaceuticals and its competitors. Ligand Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Ligand Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Ligand Pharmaceuticals (FRA:LGDN) is currently considered Significantly Overvalued. The stock's GF Value™ is €150.43, compared to a current price of €280.00 — trading 86.1% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.29. Ligand Pharmaceuticals' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Ligand Pharmaceuticals (FRA:LGDN), the current LT-Debt-to-Total-Asset is 0.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ligand Pharmaceuticals (FRA:LGDN) Overvalued in 2026?

Based on GuruFocus' analysis, Ligand Pharmaceuticals stock appears to be overvalued. The current stock price of €280.00 is trading 86.1% above its estimated GF Value™ of €150.43. GuruFocus considers Ligand Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:LGDN:

LT-Debt-to-Total-Asset: 0.29
GF Value™: €150.43 vs. price of €280.00 (86.1% above fair value)
GF Score™: 73/100 with 5 warning signs

No single metric tells the full story. See the FRA:LGDN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ligand Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies DFTX CGON XENE COGT SRRK LEGN TVTX ORKA CRSP MANE VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges LGND:USA

Address 555 Heritage Drive, Suite 200, Jupiter, FL, USA, 33458

Website https://www.ligand.com

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

73GF Score

Get the complete analysis for FRA:LGDN

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€280.00

Price

€150.43

GF Value

View FRA:LGDN Analysis

See LT-Debt-to-Total-Asset data for all stocks →